Evidence map›Paper›PMID 36542603›Full record

ArticlePLoS neglected tropical diseases2022

Evaluating the impact of alternative intervention strategies in accelerating onchocerciasis elimination in an area of persistent transmission in the West Region of Cameroon.

Kareen Atekem, Ruth Dixon, Aude Wilhelm, Benjamin Biholong, Joseph Oye, Hugues Nana Djeunga, Philippe Nwane, Franklin Ayisi, Daniel Boakye, Joseph Kamgno and 3 more

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 3 countries.

Kareen AtekemSightsavers, Cameroon Country Office, Yaoundé, Cameroon.ORCID 0000-0001-8225-1847
Ruth DixonSightsavers, Haywards Heath, United Kingdom.
Aude WilhelmSightsavers, Haywards Heath, United Kingdom.
Benjamin BiholongNational Programme for the Fight against Onchocerciasis and Lymphatic Filariasis, Ministry of Public Health, Yaoundé, Cameroon.
Joseph OyeSightsavers, Cameroon Country Office, Yaoundé, Cameroon.
Hugues Nana DjeungaFilariasis and other Tropical Diseases Research Center (CRFilMT), Yaoundé, Cameroon.
Philippe NwaneFilariasis and other Tropical Diseases Research Center (CRFilMT), Yaoundé, Cameroon.
Franklin AyisiNational Programme for the Fight against Onchocerciasis and Lymphatic Filariasis, Ministry of Public Health, Yaoundé, Cameroon.
Daniel BoakyeParasitology Department, Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana.
Joseph KamgnoFilariasis and other Tropical Diseases Research Center (CRFilMT), Yaoundé, Cameroon.
Elena SchmidtSightsavers, Haywards Heath, United Kingdom.
Rogers NditanchouSightsavers, Cameroon Country Office, Yaoundé, Cameroon.
Laura SenyonjoSightsavers, Haywards Heath, United Kingdom.
Sightsavers · GBMinistry of Public Health · CMUniversité de Yaoundé I · CMUniversity of Ghana · GH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlternative strategies are recommended to accelerate onchocerciasis elimination in problematic areas including areas where annual ivermectin (IVM) distributions are unable to interrupt transmission. The aim of this study was to accelerate progress towards elimination in the Massangam health district, West Region of Cameroon where impact evaluations demonstrated ongoing transmission of onchocerciasis infection and high microfilaria (mf) prevalence despite more than 20 years of annual IVM distribution. METHODOLOGY/PRINCIPAL

findingsParasitological, entomological, and breeding site surveys were conducted in 2015 delineating a focus of high transmission and identified three communities with high mf prevalence. Individuals in these communities were screened for mf yearly for a period of two years and those positive treated each year with doxycycline 100mg daily for five weeks. In addition, surrounding communities were given biannual IVM. Temephos-based applications were performed once a week for 10 consecutive weeks on Simulium damnosum s.l. breeding sites. Parasitological and entomological assessments were conducted after two years of implementation and findings compared with 2015 baseline. Alternative strategies accelerated progress towards elimination through a significant mf reduction (χ2: 40.1; p<0.001) from 35.7% (95%CI: 29.0-42.8) to 12.3% (95%CI, 9.0-16.4). Reductions were furthermore recorded over a longer period, with a reduction of prevalence of 29.0% under AIS in 2017-2019 compared to 14.6% with IVM in 2011-2015; and by 23.2% following the two years of alternative strategies compared to 20.3% reduction over 15 years of treatment with IVM (1996-2011). Entomological assessment demonstrates that transmission is still ongoing despite the reduction in mf which is expected in an environment with complex breeding sites and open transmission zones, i.e., where migration of flies or humans to and from neighbouring areas is common. CONCLUSION/SIGNIFICANCE: This study provides evidence that alternative strategies are feasible and effective and should be considered in areas where transmission is sustained throughout long term uninterrupted MDA with IVM. However, there is need to consider wider transmission zones, and further explore optimal timing of larviciding with treatment to impact transmission.

Indexed as

OnchocerciasisAnimalsCameroonDoxycyclineHumansIvermectinMicrofilariaeTemefosDoxycyclineIvermectinTemefos

Identifiers

PMID36542603
PMCPMC9770396
OpenAlexW4312060066

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.